Company: SVREW
Filing Date: 2025-03-21
Form Type: 20-F
Source: 0001013762-25-001028
Chunk: 173

Company: SaverOne 2014 Ltd.
Filing Date: 2025-03-21
Form: 20-F
Item: Item 19
Chunk 173
---
13 per Unit, each consisting of (i) one ADS and (ii) one Warrant exercisable for one ADS over a limited period of 5 -years from the issuance date at an ...  

  208,282 Pre-Funded Units at a price to the public of $ 4.129 per Pre-Funded Unit, each consisting of (i) one Pre-Funded Warrant exercisable for one ADS, which were exercisable immediately and m...  

In
connection with the U. S. IPO, the Company engaged a U. S. underwriter, which was granted as part of its compensation upon completion of
the U. S. IPO the Representative’s Warrant were exercisable original for 157,510 5.16 656 1,238 469,654 4.129 469,654 0.001 126,482 343,172 343,172

Upon
satisfaction of customary closing conditions, the Closing Date of the U. S. IPO was June 7, 2022.

As
the exercise price of the Warrants is determined in foreign currency and as the Warrants might be exercisable to variable number of shares
due to cashless exercise mechanism, the Warrants are accounted for as a derivative financial liability.

Moreover,
the Company received substantially all of the Pre-Funded Warrant proceeds upfront (without any conditions) as part of the Pre-Funded
Warrant’s purchase price and in return the Company was obligated to issue fixed number of ADSs to holders. Thus, Pre-Funded Warrants
were accounted for and classified as additional paid-in capital as part of the Company’s shareholders’ equity.

As
the Representative’s Warrant were granted to the underwriter as compensation for its underwriting services rendered in respect
to the U. S. IPO, they were accounted for under IFRS 2 “ Share-based Payment” in total amount of NIS 5 588 463 0 2.16 3.11 52.92 2.76

F-35

SAVERONE
2014 LTD.

NOTES
TO THE FINANCIAL STATEMENTS (CONT.)

(New
Israeli Shekels in thousands, except per share and share data)

Note
13 - Share capital and reserves (Cont.)

  Changes                                        
  in the issued and outstanding capital (Cont.)  
 ─────────────────────────────────────────────────

  (1)      (Cont.)  

Pursuant
to the above